Status:
COMPLETED
OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer
Lead Sponsor:
Ohio State University Comprehensive Cancer Center
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Carcinoma, Non-Small-Cell Lung
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study determines tumor response rate, time to tumor progression and survival rate at 1 year produced by OSI-774 in previously treated African American patients with nonsmall cell lung cancer.
Detailed Description
Rationale: Researchers are seeking to identify treatment regimens with low toxicity for non-small cell lung cancer (NSCLC), especially for African Americans with this disease who seem to have a larger...
Eligibility Criteria
Inclusion
- Must have histologically or cytologically confirmed stage IIIB or IV NSCLC treated with 1-2 platinum- or taxane-containing regimens
- Measurable disease
- May have had prior surgery \& external beam radiation
- African American
- 18 years or older
Exclusion
- Known brain mets
- Prior treatment with EGFR targeting therapies
- Pregnant/lactating women
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2013
Estimated Enrollment :
57 Patients enrolled
Trial Details
Trial ID
NCT00230126
Start Date
October 1 2005
End Date
July 1 2013
Last Update
December 26 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ohio State University
Columbus, Ohio, United States, 43210